Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Recommendation of “Hold” from Brokerages

Medpace Holdings, Inc. (NASDAQ:MEDP) has been given a consensus rating of “Hold” by the thirteen research firms that are covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $376.30.

Several analysts recently commented on MEDP shares. Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Leerink Partners started coverage on shares of Medpace in a research note on Monday. They set a “market perform” rating and a $330.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research note on Monday.

Medpace Stock Performance

Shares of MEDP opened at $316.61 on Friday. The stock has a 50-day moving average of $336.40 and a two-hundred day moving average of $339.26. The stock has a market cap of $9.65 billion, a P/E ratio of 25.07, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace has a one year low of $302.01 and a one year high of $459.77.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Analysts predict that Medpace will post 12.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. R Squared Ltd acquired a new position in shares of Medpace during the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. purchased a new position in Medpace in the 4th quarter valued at $31,000. Jones Financial Companies Lllp boosted its stake in Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares during the last quarter. Lindbrook Capital LLC boosted its stake in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after purchasing an additional 29 shares during the last quarter. Finally, True Wealth Design LLC grew its holdings in shares of Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after buying an additional 168 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.